Retrieval of lost patients in the system for hepatitis C microelimination: a single-center retrospective study
| Autor: | Yang-Yuan Chen, Pei-Yuan Su, Po-Ke Hsu, Ya-Huei Zeng, Siou-Ping Huang, Yu-Chun Hsu, I.-L.ing Liu, Hsu-Heng Yen |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Liver Cirrhosis
medicine.medical_specialty Cirrhosis Hepatitis C virus Hepacivirus RC799-869 Chronic liver disease medicine.disease_cause Single Center Antiviral Agents 03 medical and health sciences 0302 clinical medicine Internal medicine Medicine Humans Retrospective Studies business.industry Research Gastroenterology virus diseases Retrospective cohort study General Medicine Hepatitis C Hepatology Hepatitis C Antibodies Hepatitis C Chronic Diseases of the digestive system. Gastroenterology medicine.disease digestive system diseases 030220 oncology & carcinogenesis 030211 gastroenterology & hepatology business Liver cancer |
| Zdroj: | BMC Gastroenterology, Vol 21, Iss 1, Pp 1-7 (2021) BMC Gastroenterology |
| Popis: | Background Hepatitis C virus (HCV) is one of the major causes of chronic liver disease, cirrhosis, and liver cancer. Most of the infected people have no clinical symptoms. The current strategy for HCV elimination includes test and treatment. In this study, we aimed to evaluate the campaign for retrieving patients who were lost to follow-up, for subsequent re-evaluation. Methods From January 2020 to October 2020, patients who had prior tests for positive anti-HCV antibody in 2010–2018 in our hospital were enrolled for our patient callback campaign. Patients who had unknown HCV RNA status or no documented successful antiviral therapy history were selected for anti-HCV therapy re-evaluation. To facilitate patient referral in the hospital, we developed an electronic reminding system and called the candidate patients via telephone during the study period. Results Through the hospital electronic system, 3783 patients with positive anti-HCV antibody documentation were identified. Among them, 1446 (38.22%) had tested negative for HCV RNA or had anti-HCV therapy, thereby excluded. Of the 2337 eligible patients, 1472 (62.99%) were successfully contacted and called back during the study period for subsequent HCV RNA testing and therapy. We found that 42.19% of the patients had positive HCV RNA and 88% received subsequent anti-HCV therapy. Conclusions A significant number of patients with positive HCV serology were lost for HCV confirmatory test or therapy in the hospital. Therefore, this targeted HCV callback approach in the hospital is feasible and effective in achieving microelimination. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|